Literature DB >> 8385109

Relationship between defective mouse mammary tumor virus envelope glycoprotein synthesis and GRP78 synthesis in glucocorticoid-treated mouse lymphoma cells. Evidence for translational control of GRP78 synthesis.

L M Ulatowski1, M Lam, G Vanderburg, M R Stallcup, C W Distelhorst.   

Abstract

We have found that synthesis of the 78-kDa glucose-regulated protein, GRP78, was increased following glucocorticoid treatment of S49 and W7MG1 mouse lymphoma cell lines. These lines synthesized a 74-kDa mouse mammary tumor virus envelope glycoprotein precursor, Pr74, both constitutively and in response to glucocorticoid treatment. In these cell lines, nascent Pr74 was not processed normally but was retained within the endoplasmic reticulum where it was bound stably by GRP78. GRP78 synthesis was not increased following glucocorticoid treatment of the W7.2 mouse lymphoma cell line, which does not synthesize Pr74, suggesting that the increase in GRP78 synthesis following glucocorticoid treatment of S49 and W7MG1 cells was secondary to the glucocorticoid-induced increase in Pr74 synthesis. Consistent with this hypothesis, the glucocorticoid-induced increase in Pr74 synthesis preceded the increase in GRP78 synthesis. Also, there was a direct correlation between the level of GRP78 synthesis and the level of Pr74 synthesis among multiple subclones of the W7-ENV/N line. This line was derived from the W7.2 line by retroviral mediated transfer of a constitutively expressed sequence encoding a defective form of Pr74 that was bound stably by GRP78 within the endoplasmic reticulum. An elevation in the steady state level of GRP78 mRNA was not detected either in glucocorticoid-treated S49 cells and W7MG1 cells or in subclones of the W7-ENV/N line that have an increased level of GRP78 synthesis. Therefore, it appears that the binding of Pr74 to GRP78 induces an increase in GRP78 synthesis that is regulated at a translational level, rather than at a transcriptional level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385109

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  La autoantigen enhances translation of BiP mRNA.

Authors:  Y K Kim; S H Back; J Rho; S H Lee; S K Jang
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

2.  Human cytomegalovirus induces the endoplasmic reticulum chaperone BiP through increased transcription and activation of translation by using the BiP internal ribosome entry site.

Authors:  Nicholas J Buchkovich; Yongjun Yu; Francis J Pierciey; James C Alwine
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

3.  BiP internal ribosomal entry site activity is controlled by heat-induced interaction of NSAP1.

Authors:  Sungchan Cho; Sung Mi Park; Tae Don Kim; Jong Heon Kim; Kyong-Tai Kim; Sung Key Jang
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

4.  Differential regulation of GRP78 and GLUT1 expression in 3T3-L1 adipocytes.

Authors:  H H Kitzman; R J McMahon; A M Aslanian; P M Fadia; S C Frost
Journal:  Mol Cell Biochem       Date:  1996-09-06       Impact factor: 3.396

5.  Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME.

Authors:  C Jamora; G Dennert; A S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Activation profiles of HSPA5 during the glomerular mesangial cell stress response to chemical injury.

Authors:  Hadi Falahatpisheh; Adrian Nanez; Diego Montoya-Durango; Yongchang Qian; Evelyn Tiffany-Castiglioni; Kenneth S Ramos
Journal:  Cell Stress Chaperones       Date:  2007       Impact factor: 3.667

7.  Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins.

Authors:  D Thomas Rutkowski; Stacey M Arnold; Corey N Miller; Jun Wu; Jack Li; Kathryn M Gunnison; Kazutoshi Mori; Amir A Sadighi Akha; David Raden; Randal J Kaufman
Journal:  PLoS Biol       Date:  2006-11       Impact factor: 8.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.